Generic placeholder image

Current Pharmaceutical Design


ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

IL-19 as a Potential Therapeutic in Autoimmune and Inflammatory Diseases

Author(s): Yasu-Taka Azuma, Hidemitsu Nakajima and Tadayoshi Takeuchi

Volume 17, Issue 34, 2011

Page: [3776 - 3780] Pages: 5

DOI: 10.2174/138161211798357845

Price: $65


Interleukin-19 (IL-19) is a member of the IL-10 family of cytokines. The last ten years from the finding of IL-19, investigations underline the role of IL-19 in the immunological diseases. It is known that expression of IL-19 is increased in the epidermis of patients with psoriasis, which is a Th1 dominant disease. Increased concentration of IL-19 has also been found in the serum of patients with asthma, which is a Th2 dominant disease. There is an increasing body of data demonstrating that IL-19 is associated with the pathogenesis of both Th1 and Th2 dominant diseases. Regarding the role of IL-19 on the innate immunity and inflammation, interestingly, in vitro studies have shown that lipopolysaccharide can stimulate human monocytes and macrophages to upregulate the expression of IL-19. IL- 19 is upregulated in macrophages after infection and lessens inflammation by suppressing the production of tumor necrosis factor-α, IL-6 and IL-12, but not by inducing IL-10. In addition, IL-19-deficient mice are susceptible to experimental colitis induced by dextran sodium sulfate, a disease which is characterized by excessive inflammatory responses of local macrophages and epithelial cells to intestinal microflora. In this review, we discuss our current understanding of the role of IL-19 in autoimmune and inflammatory diseases.

Keywords: Immune system disease, cytokines, macrophage, T cell, keratinocyte, asthmas, inflammatory bowel disease, psoriases, B-cells, skin inflammation

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy